{"id":70879,"date":"2026-07-29T18:30:20","date_gmt":"2026-07-29T10:30:20","guid":{"rendered":"https:\/\/flcube.com\/?p=70879"},"modified":"2026-07-29T18:30:21","modified_gmt":"2026-07-29T10:30:21","slug":"humanwell-healthcares-non-opioid-analgesic-hw243040-receives-nmpa-approval-for-peripheral-neuropathic-pain-clinical-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70879","title":{"rendered":"Humanwell Healthcare&#8217;s Non-Opioid Analgesic HW243040 Receives NMPA Approval for Peripheral Neuropathic Pain Clinical Trials"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Humanwell Healthcare<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/600079:SHA\">SHA: 600079<\/a>) announced that its novel drug candidate <strong>HW243040<\/strong> has received <strong>clinical trial approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>peripheral neuropathic pain (pNP)<\/strong>, positioning the company to address a significant unmet medical need with a non-opioid therapeutic approach.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Humanwell Healthcare (SHA: 600079)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>HW243040<\/td><\/tr><tr><td><strong>Regulatory Agency<\/strong><\/td><td>National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Peripheral neuropathic pain (pNP)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>29 Jul 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Initiation of Phase I clinical studies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-disease-background-amp-market-need\" class=\"wp-block-heading\">Disease Background &amp; Market Need<\/h2>\n\n\n\n<h3 id=\"h-neuropathic-pain-landscape\" class=\"wp-block-heading\">Neuropathic Pain Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Definition:<\/strong> Chronic pain condition caused by lesions or diseases affecting the somatosensory nervous system<\/li>\n\n\n\n<li><strong>Classification:<\/strong> Divided into <strong>peripheral neuropathic pain (pNP)<\/strong> and central neuropathic pain<\/li>\n\n\n\n<li><strong>Prevalence:<\/strong> pNP represents the more common form with substantial patient burden<\/li>\n\n\n\n<li><strong>Clinical Course:<\/strong> Characterized by prolonged duration or recurrent flare-ups<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-patient-impact-amp-current-gaps\" class=\"wp-block-heading\">Patient Impact &amp; Current Gaps<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Comorbidities:<\/strong> Frequently accompanied by sleep disorders, anxiety, and depression<\/li>\n\n\n\n<li><strong>Quality of Life:<\/strong> Severely impacts daily functioning and overall well-being<\/li>\n\n\n\n<li><strong>Treatment Limitations:<\/strong> Existing options often inadequate, with significant side effect profiles<\/li>\n\n\n\n<li><strong>Opioid Concerns:<\/strong> Current analgesics carry risks of dependence, addiction, and CNS-related adverse effects<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-drug-profile-amp-differentiation\" class=\"wp-block-heading\">Drug Profile &amp; Differentiation<\/h2>\n\n\n\n<h3 id=\"h-mechanism-of-action\" class=\"wp-block-heading\">Mechanism of Action<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Class:<\/strong> <strong>Non-opioid analgesic<\/strong><\/li>\n\n\n\n<li><strong>Novel Target:<\/strong> Unique <strong>peripheral immune-neuro-modulatory mechanism<\/strong><\/li>\n\n\n\n<li><strong>Safety Advantage:<\/strong> Designed to avoid <strong>central nervous system-related side effects<\/strong><\/li>\n\n\n\n<li><strong>Addiction Risk:<\/strong> Eliminates concerns regarding <strong>drug dependence and addiction<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-clinical-value-proposition\" class=\"wp-block-heading\">Clinical Value Proposition<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targeted Approach:<\/strong> Addresses root cause through peripheral mechanism rather than CNS modulation<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Potential for improved tolerability compared to existing analgesics<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Suitable for long-term management given chronic nature of pNP<\/li>\n\n\n\n<li><strong>Therapeutic Innovation:<\/strong> Represents new mechanistic approach in crowded pain management space<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<h3 id=\"h-for-humanwell-healthcare\" class=\"wp-block-heading\">For Humanwell Healthcare<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Diversification:<\/strong> Expands company&#8217;s presence beyond traditional pharmaceutical segments<\/li>\n\n\n\n<li><strong>Innovation Credibility:<\/strong> Demonstrates R&amp;D capability in complex neurological indications<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> Addresses large, underserved patient population with significant unmet needs<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Leverages China&#8217;s supportive environment for innovative pain therapeutics<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-context\" class=\"wp-block-heading\">Competitive Context<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Non-Opioid Focus:<\/strong> Aligns with global trend toward safer pain management alternatives<\/li>\n\n\n\n<li><strong>Mechanistic Novelty:<\/strong> Differentiates from existing anticonvulsants, antidepressants, and topical agents<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> Successful development could capture meaningful share in multi-billion dollar neuropathic pain market<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial expectations. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600079_20260729_JVYV-1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600079_20260729_JVYV.\"><\/object><a id=\"wp-block-file--media-fcbf2148-3a3d-4911-8d57-0c8b53d4b265\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600079_20260729_JVYV-1.pdf\">600079_20260729_JVYV<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600079_20260729_JVYV-1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-fcbf2148-3a3d-4911-8d57-0c8b53d4b265\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Humanwell Healthcare (SHA: 600079) announced that its novel drug candidate HW243040 has received clinical trial&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,266,1098],"class_list":["post-70879","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-humanwell-healthcare","tag-sha-600079"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Humanwell Healthcare&#039;s Non-Opioid Analgesic HW243040 Receives NMPA Approval for Peripheral Neuropathic Pain Clinical Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Humanwell Healthcare (SHA: 600079) announced that its novel drug candidate HW243040 has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for the treatment of peripheral neuropathic pain (pNP), positioning the company to address a significant unmet medical need with a non-opioid therapeutic approach.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70879\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Humanwell Healthcare&#039;s Non-Opioid Analgesic HW243040 Receives NMPA Approval for Peripheral Neuropathic Pain Clinical Trials\" \/>\n<meta property=\"og:description\" content=\"Humanwell Healthcare (SHA: 600079) announced that its novel drug candidate HW243040 has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for the treatment of peripheral neuropathic pain (pNP), positioning the company to address a significant unmet medical need with a non-opioid therapeutic approach.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70879\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-29T10:30:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-29T10:30:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70879#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70879\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Humanwell Healthcare&#8217;s Non-Opioid Analgesic HW243040 Receives NMPA Approval for Peripheral Neuropathic Pain Clinical Trials\",\"datePublished\":\"2026-07-29T10:30:20+00:00\",\"dateModified\":\"2026-07-29T10:30:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70879\"},\"wordCount\":405,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Humanwell Healthcare\",\"SHA: 600079\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70879#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70879\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70879\",\"name\":\"Humanwell Healthcare's Non-Opioid Analgesic HW243040 Receives NMPA Approval for Peripheral Neuropathic Pain Clinical Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-29T10:30:20+00:00\",\"dateModified\":\"2026-07-29T10:30:21+00:00\",\"description\":\"Humanwell Healthcare (SHA: 600079) announced that its novel drug candidate HW243040 has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of peripheral neuropathic pain (pNP), positioning the company to address a significant unmet medical need with a non-opioid therapeutic approach.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70879#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70879\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70879#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Humanwell Healthcare&#8217;s Non-Opioid Analgesic HW243040 Receives NMPA Approval for Peripheral Neuropathic Pain Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Humanwell Healthcare's Non-Opioid Analgesic HW243040 Receives NMPA Approval for Peripheral Neuropathic Pain Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","description":"Humanwell Healthcare (SHA: 600079) announced that its novel drug candidate HW243040 has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of peripheral neuropathic pain (pNP), positioning the company to address a significant unmet medical need with a non-opioid therapeutic approach.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70879","og_locale":"en_US","og_type":"article","og_title":"Humanwell Healthcare's Non-Opioid Analgesic HW243040 Receives NMPA Approval for Peripheral Neuropathic Pain Clinical Trials","og_description":"Humanwell Healthcare (SHA: 600079) announced that its novel drug candidate HW243040 has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of peripheral neuropathic pain (pNP), positioning the company to address a significant unmet medical need with a non-opioid therapeutic approach.","og_url":"https:\/\/flcube.com\/?p=70879","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-29T10:30:20+00:00","article_modified_time":"2026-07-29T10:30:21+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70879#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70879"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Humanwell Healthcare&#8217;s Non-Opioid Analgesic HW243040 Receives NMPA Approval for Peripheral Neuropathic Pain Clinical Trials","datePublished":"2026-07-29T10:30:20+00:00","dateModified":"2026-07-29T10:30:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70879"},"wordCount":405,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Humanwell Healthcare","SHA: 600079"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70879#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70879","url":"https:\/\/flcube.com\/?p=70879","name":"Humanwell Healthcare's Non-Opioid Analgesic HW243040 Receives NMPA Approval for Peripheral Neuropathic Pain Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-29T10:30:20+00:00","dateModified":"2026-07-29T10:30:21+00:00","description":"Humanwell Healthcare (SHA: 600079) announced that its novel drug candidate HW243040 has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of peripheral neuropathic pain (pNP), positioning the company to address a significant unmet medical need with a non-opioid therapeutic approach.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70879#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70879"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70879#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Humanwell Healthcare&#8217;s Non-Opioid Analgesic HW243040 Receives NMPA Approval for Peripheral Neuropathic Pain Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70879"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70879\/revisions"}],"predecessor-version":[{"id":70882,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70879\/revisions\/70882"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}